

Mechanisms of hepatocarcinogenesis

Raphaël Saffroy (1), Antoinette Lemoine (1), Brigitte Debuire (1)

1) Service de Biochimie et Biologie moléculaire; U602 Inserm/Université Paris XI; Hôpital Paul Brousse, 14 avenue Paul Vaillant Couturier - 94804 Villejuif Cedex, Assistance Publique-Hôpitaux de Paris ; France.

September 2006

[Hepatocellular carcinoma \(HCC\)](#) is among the fifth most common cancers worldwide. The geographic areas at higher risk are located in China and eastern Asia, middle Africa and some countries of western Africa. Lower incidences are encountered in Japan, Europe and America, but this incidence is still rising in part because of the high level of hepatitis C virus infection. The preponderance in males is universal and HCC is the commonest in subjects over the age of 40, although it can be observed in younger. The prognosis is generally poor, especially in Africans and Chinese where survival time may be as short as 11 weeks from the onset of symptoms. The causes of more than 85% of HCC cases are known (hepatitis B and C, aflatoxin B1, ethanol, metabolic diseases). HCC is an epithelial tumor developing from hepatocytes. In the majority of cases, cirrhosis is the major underlying risk factor, but HCC may occur also on chronic hepatitis or normal liver.

Mechanisms of hepatocarcinogenesis are not completely understood but, like most solid tumors, the development and progression of HCC are believed to be caused by the accumulation of genetic changes resulting in altered expression of cancer-related genes, such as oncogenes or tumor suppressor genes, as well as genes involved in different regulatory pathways. The genetic changes involved can be divided in at least 4 different pathways, each pathway contributing to a limited number of tumors. These are :

1. the *p53* pathway involved in response to DNA damage,
2. the *retinoblastoma* pathway involved in control of the cell cycle,
3. the *transforming growth factor-beta* (TGF-beta) pathway involved in growth inhibition, and
4. the *Wnt* pathway involved in cell-cell adhesion and signal transduction.

Sequential changes in the liver leading to HCC

HCC is probably one of the tumors the etiologic factors of which are the best known. However, in spite of numerous studies and thousands of tumors analyzed, fractionnal data relative to the genetic mechanisms of hepatocarcinogenesis are known and genetic predisposition has been rarely described. HCC generally develops in the setting of chronic hepatitis or cirrhosis in which there is continuous inflammation and regeneration of hepatocytes (Figure 1).




Figure 1 : Sequential changes in the liver leading to HCC

Hepatocarcinogenesis may begin in preneoplastic lesions such as macroregenerative nodules, low-grade and high grade dysplastic nodules (Takayama *et al*, 1990; Orsatti *et al*, 1993). Accelerated proliferation of hepatocytes and development of monoclonal hepatocyte populations occur in all preneoplastic conditions. Accumulation of genetic alterations in these preneoplastic lesions is believed to lead to the development of HCC. Genomic alterations occur randomly, and they accumulate in dysplastic hepatocytes and HCC. Although genetic changes may occur independently of etiologic conditions, some molecular mechanisms have been more frequently related to a specific etiology. For example, molecular pathways of HBV- and HCV-induced hepatocarcinogenesis involving Rb1, p53, and Wnt families are different from those associated with alcoholism (Wang *et al*, 2002; Suriawinata *et al*, 2004, Morgan *et al*, 2004).

Alterations during the preneoplastic phase

The important heterogeneity of genomic lesions found in HCC suggests that HCC may be produced by selection of both genomic and epigenetic alterations that compromise more than one regulatory pathway. During the preneoplastic stage leading to HCC, alterations concern mainly quantitative modification of gene expression induced by epigenetic mechanisms. Growth factor genes such as *transforming growth factor-1 (TGF- α)* or *insulin growth factor-2 (IGF-2)* are mainly involved. Dysregulation of these genes results from combined actions of cytokines produced by chronic inflammatory cells that infiltrate the liver and the regenerative response of the liver, viral transactivation, or action of carcinogens. Genome-wide hypomethylation and aberrant methylation of genes and chromosomal segments are also observed. Expression of DNA methyltransferases which catalyze the methylation and demethylation of CpG groups is increased in livers affected with cirrhosis and chronic hepatitis (Lin *et al*, 2001). Cis- and transactivation of genes resulting from the actions of integrated viral promoters or viral transactivating molecules are other possible causes of epigenetic changes. For example, during HBV chronic infection, the HBx antigen binds and alters functionally tumor suppressor P53. Moreover, integration of viral genome sequences may induce genomic instability and structural changes such as mutations, breaks or chromosomal rearrangements. These early genetic or epigenetic alterations are not sufficient to induce malignant phenotypes in hepatocytes. It is the accumulation of these events in critical combinations that allow the malignant transformation, several genes being simultaneously altered in each tumor.

Alterations in HCC

Microsatellite instability (MSI) has been frequently reported by different teams, including in liver cirrhosis, mainly when cirrhosis is associated with HBV infection (Salvucci *et al*, 1996; Salvucci *et al*, 1999; Karachristos *et al*, 1999; Kondo *et al*, 1999; Kawai *et al*,

2000; Dore *et al*, 2001). However, the frequency of MSI in HCC exhibits large variations (10-43%) and high-MSI phenotype has rarely been described (MacDonald *et al*, 1998; Chiappini *et al*, 2004). It is still unclear whether some HCC have DNA mismatch repair genes alterations. Allelic deletions, mainly in chromosomes 1p, 4q, 5q, 6q, 7p, 8p, 9p, 10q, 11p, 13q, 16p, 16q *et al*, 2002 and 17p, or gains in chromosomes 1p, 6p, 8q and 17q are frequently observed (Thorgeirsson). This genomic instability contributes to activation or inactivation of oncogenes or tumor suppressor genes. In some cases, epigenetic changes directly precede structural alterations in the same genes as it has been described for *CDKN2A* gene in 16q chromosome or *c-myc* oncogene in 8q. Some carcinogens may induce specific alterations. Indeed, aflatoxin B1 is responsible of a G/T transversion at codon 249 in the *p53* gene. Complete erosion of telomeres, which may exist in highly replicated preneoplastic and neoplastic hepatocytes, may also contribute to genomic instability and could play a cooperative role with altered *p53* in the progression of hepatocellular carcinoma (Farazi *et al*, 2006). Moreover oxidative damage occurring in a chronically inflamed liver can lead to mutations in genomic, but also in mitochondrial DNA (Seitz *et al*, 2006). Production of new genetic alterations in clones of malignant hepatocytes leads to clonal divergence. Finally, HCC appears as a diverse mixture of genomic aberrations in which more than one signal pathway is affected. Some genes have been clearly identified to play a role in hepatocarcinogenesis. But other genes are suspected, sometimes because of high frequencies of allelic deletions in some chromosomal segments (table 1).

Table 1 . Main candidate tumor suppressor genes located in chromosomal segments with high level of loss of heterozygosity in HCC.

LOH	Candidate genes
1p	p73, RIZ (<i>retinoblastoma-interacting zinc-finger protein</i>)
2p	<u>hMSH2</u>
3p	<u>hMLH1</u>
5q	<u>APC</u>
6q	<u>M6P/IGFIIR</u> (<i>mannose 6-phosphate/insulin-like growth factor II receptor</i>)
9p	<u>CDKN2A</u> (<i>ou p16INK4A, MTS1/p16</i>)
10q	<u>PTEN/MMAC1</u>
13q	<u>RB</u> (<i>retinoblastoma</i>), <i>BRCA2</i>
16p	<i>axine 1</i> ,
16q	<i>CDH13</i>
17p	<u>p53</u>

Late events in hepatocarcinogenesis (metastasis)

Lack of control of recurrence and metastatic foci is the most prevalent cause of death in patients with HCC. HCC metastasis is probably initiated in the primary tumor and is a multigene-involved, multistep, and changing process. The molecular signature of primary hepatocellular carcinoma (HCC) has been found very similar to that of their corresponding metastases, while it differs significantly in primary HCCs with or without metastasis. These findings imply that many of the metastasis-promoting genes are embedded in the primary tumors and that the ability to metastasize may be an inherent quality of the tumor from the beginning (Budhu *et al*, 2005). Allelic losses have been proposed as being related to the survival and prognosis of cancer patients. Loss of heterozygosity (LOH) on chromosomes 13q, 16q, and 17p has been particularly associated with the progression of HCC. LOH on 16q has been

identified as one of the most significant negatively predictive factors for metastasis-free survival of HCC patients (Salvucci *et al*, 1999; Okabe *et al*, 2000; Nishida *et al*, 2002, Gross-Goupil *et al*, 2003). Nevertheless, the genes altered have not still been identified. Metastatic process need intercellular exchange between tumoral cells and environmental cells such as endothelial cells or fibroblasts. Different molecules may be involved in these interactions. Some adhesion molecules are suspected to play a role in the metastatic process in HCC such as laminin-5 (Giannelli *et al*, 2003), variants of CD44 glycoprotein (Endo *et al*, 2000), or osteopontin (Pan *et al*, 2003, Ye *et al*, 2003). Proteins involved in the degradation of the extracellular matrix may also play an important role such as urokinase plasminogen activator / plasminogen activator inhibitor-1 (uPA/PAI-1) (Zheng *et al*, 2000) or matrix metalloproteinases (Giannelli *et al*, 2002). Angiogenesis is critical to HCC since it is such a hypervascular tumor. Various angiogenic factors have been identified in HCC. In particular VEGF and its receptors have been demonstrated to be upregulated in HCC both at the tissue and serum levels.

Main genes involved in HCC

Gene p53

P53 protein is a DNA-binding, cell regulating, transcription factor that has multiple critical roles in the pathway governing cell-cycle and in the balance between cell division and apoptosis. The *p53* gene is the most commonly mutated tumor suppressor gene in various human cancers. The frequency and type of *p53* mutations differ according to the geographic origin and suspected etiology of HCC. The specific codon 249 mutation has been linked to aflatoxin exposure in 36% of tumors from Africa and 32% of tumors from China, respectively (Ozturk *et al*, 1999). In contrast, the codon 249 mutation is seen in less than 4% of HCCs from Japan, Europe, and north America, where HBV and HCV, but not aflatoxins, are the main etiologic factors. Other codons of the *p53* gene can be altered in HCC and overall this gene is mutated in 15% of tumors in Europe and 42% in China. The wild-type P53 protein can accumulate in HCC tumor cells by complexing with cellular or viral proteins (Bourdon *et al*, 1995). Experimentally, the HBx protein, encoded by the HBV genome, interacts with wild-type P53 and inhibit its function. Moreover, P53 antibodies have been detected in the serum of HCC patients (Shiota *et al*, 1997; Saffroy *et al*, 1999; Charuruks *et al*, 2001). P53 alterations have been globally associated with poor prognosis.

b-catenin and the Wnt pathway

b-catenin is a submembranous protein associated with E-cadherin and participates in cell-cell adhesion. It is involved in the Wnt carcinogenesis pathway. The Wnt signal inducing cellular proliferation implicates formation of a complex with axin, GSK-3 β kinase and APC proteins and finally degradation of *b*-catenin. Dysregulation of the Wnt pathway inhibits these complexes and induces *b*-catenin stabilization. Translocation of *b*-catenin to the nucleus causes transcriptional activation of target genes, including the [c-myc](#) and [cyclin D1](#) genes. Most of *b*-catenin point mutations alter 1 of the 4 serine or threonine residues which are targets for phosphorylation by GSK3- β and are crucial for down-regulation of the protein. *b*-catenin mutations have been found in 19 to 41% of human HCCs of different etiologies (de la coste *et al*, 1998; legoix *et al*, 1999). Clinical significance of intense nuclear localization of *b*-catenin in HCC is controversial (Terris *et al* 1999; Hsu *et al*, 2000; Endo *et al*, 2000; Wong *et al*, 2001; Fujito *et al*, 2004). It has been shown that *b*-catenin mutations are more prevalent in HCCs related to HCV than HBV (Laurent-Puig *et al*, 2001). They have not been detected in non tumorous tissue, dysplastic lesions, and cirrhotic nodules. HCCs harboring *b*-catenin mutations have a limited number of chromosomal aberrations detected by microsatellite marker analysis (Legoix *et al*, 1999, Hsu *et al*, 2000, Laurent Puig *et al*, 2001) suggesting an independant mechanism of hepatocarcinogenesis. In mouse models of hepatocarcinogenesis, the incidence of *b*-catenin mutations is highly variable between tumors induced by different carcinogens (Devereux *et al*, 1999) or developed on different *p53* backgrounds (Renard *et al*, 2000). Mutant *b*-catenin is not associated with metastases in HCC patients. This suggests that *b*-catenin mutation is an early event in hepatocarcinogenesis (Mao *et al*, 2001).

No mutations of *APC* gene have been observed in HCC, but other actors of the Wnt pathway may be altered. Indeed, *axin 1* gene is mutated in about 5-10% of HCCs (Satoh *et al*, 2000; Taniguchi *et al*, 2002). Although frequent alteration of E-cadherin expression has been observed, no mutation of the gene has been found. Loss of E-cadherin function may be related to LOH associated with *de novo* methylation (Kanai *et al*, 1997).

Taken together, the *b*-catenin pathway appears to be altered in more than one third of the HCCs.

Retinoblastoma and cell-cycle regulators

The *Retinoblastoma (Rb)* gene is involved in regulation of the G1 phase of the cell-cycle. It is the first tumor suppressor gene identified and one of the most frequently mutated in human tumors. Although *Rb* expression is frequently decreased in HCCs, mutations are observed in only 15% of the tumors (Ozturk *et al*, 1999). So inactivation of *Rb* may be further related to alterations of other interacting proteins such as *p16-INK4*. Both germline and somatic mutations of *p16-INK4* have been found in HCC patients. But hypermethylation of the gene promoter (reported in about 50% of the tumors) associated with loss of heterozygosity seems here the main mechanism for gene inactivation. Other genes are less frequently altered. Cyclin D, A or E were shown to be amplified in 10-20% of HCCs. A surexpression of *cdc2* has also been described associated with poor prognosis (Qin *et al*, 2002). Overexpression of *p28/gankyrin*, a gene involved in the degradation of *Rb* by the proteasome system, could also contribute to the metastasis potential in the process of hepatocarcinogenesis (Fu *et al*, 2002; Dawson *et al*, 2006).

TGF-beta pathway

Loss of the response to TGF- β , which induces both growth inhibition and apoptosis in hepatocytes, may also play a role in hepatocarcinogenesis. The *mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R)*, involved in the activation of TGF- β and degradation of IGF2, is a candidate gene. But if loss of heterozygosity is frequently observed at 6q25, presence of mutations in the *M6P/IGF2R* locus, is controversial. *SMAD2* and *SMAD4* are intracellular mediators of TGF- β . Nevertheless, these genes appear to be mutated in less than 10% of HCCs (Yakicier *et al*, 1999). In contrast, no mutation of TGF- β receptor II was found in HCC. Overall, the TGF- β pathway appears to be altered in about 25% of HCCs.

ras and myc oncogenes

By contrast to other types of cancer, oncogenes do not seem to play an important role in hepatocarcinogenesis. However, surexpression and amplification of *c-myc* (located in 8q) have been observed in some cases. Mutation of the 3 main ras genes have been observed in less than 10% of HCCs. Some *K-ras* mutations have been related to vinyl chloride exposure.

In conclusion, the number of altered genes in HCC is high, but the frequency of each individual gene mutations is generally low. The main pathways affected may represent individually a distinct step of hepatocarcinogenesis but they probably are related to each other. To date, our knowledge of the order of events for the initiation and progression of HCC is still incomplete. Prospectively, development of global methods of analysis such as proteomics or microarray methods will probably increase discovery of new genes or pathways involved in hepatocarcinogenesis.

References

1. Bourdon JC, D'errico A, Paterlini P, Grigioni W, May E, Debuire B. P53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. *Gastroenterology*; 108: 1176-1182.
2. Budhu AS, Zipser B, Forques M, Ye QH, Sun Z, Wang XW. The molecular signature of metastases of human hepatocellular carcinoma. *Oncology* 2005; 69 Suppl1: 23-27.
3. Charuruks N, Tangkijvanich P, Voravud N, Chatsantikul R, Theamboonlers A, Poovorawan Y. Clinicla significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. *J Gastroenterol* 2001; 36: 830-836.
4. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veillhan LA, Delvart V, Chevalier S, Bismuth H, Debuire B, Lemoine A. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. *Carcinogenesis* 2004; 25: 541-547.
5. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. Gankyrin: a new oncoprotein and regulator of pRb and p53. *Trends Cell Biol* 2006; 16: 229-233.
6. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. *Proc Natl Acad Sci USA* 1998; 95: 8847-8851.

7. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. *Oncogene* 1999; 18: 4726-4733.
8. Dore MP, Realdi G, Mura D, Onida A, Massarelli G, Dettori G, Graham DY, Sepulveda AR. Genomic instability in chronic viral hepatitis and hepatocellular carcinoma. *Hum Pathol* 2001; 32: 698-703.
9. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. *Hum Pathol* 2000; 31: 558-565.
10. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. *Cancer Res* 2006; 66: 4766-4773.
11. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. *World J Gastroenterol* 2002; 8: 638-643.
12. Fujito T, Sasaki Y, Iwao K, Miyoshi Y, Tamada T, Ohigashi H, Ishikawa O, Imaoka S. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma. *Hepatogastroenterology* 2004; 51: 921-924.
13. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. *Int J cancer* 2002; 97: 425-431.
14. Giannelli G, Fransvea E, Bergamini C, Marinosci F, Antonaci S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. *Clin Cancer Res* 2003; 9: 3684-3691.
15. Gross-Goupil M, Riou P, Emile JF, Saffroy R, Azoulay D, Lacherade I, Receveur A, Piatier-Tonneau D, Castaing D, Debuire B, Lemoine A. Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation. *Int J Cancer* 2003; 104: 745-751.
16. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. *Am J Pathol* 2000; 157: 763-770.
17. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, Hirohashi S. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. *Int J cancer* 1997; 71: 355-359.
18. Karachristos A, Liloglou T, Field JK, Deligiorgi E, Kouskouni E, Spandidos DA. Microsatellite instability and p53 mutations in hepatocellular carcinoma. *Mol Cell Biol Res Commun* 1999; 2: 155-161.
19. Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, Kuroiwa T, Igarashi M, Tsukada K, Mori S, Shimizu T, Suzuki Y, Abe Y, Takahashi T, Nomoto M, Asakura H. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. *Hepatology* 2000; 31: 1246-1250.
20. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis. *J Hepatol* 1999 ; 31 : 529-536.
21. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. *Gastroenterology* 2001; 120: 1763-1773.
22. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. *Oncogene* 1999; 18: 4044-4046.
23. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, Liaw YF. Genome-wide hypomethylation in hepatocellular carcinogenesis. *Cancer Res* 2001; 61: 4238-4243.
24. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. *J Pathol* 2001; 193: 95-101.
25. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. *Hepatology* 1998; 28: 91-97.
26. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. *Gastroenterology* 2004; 127: S87-96.
27. Nishida N, Fukuda Y, Komeda T, Ito T, Nishimura T, Minata M, Kuno M, Katsuma H, Ikai I, Yamaoka Y, Nakao K. Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. *Oncology* 2002; 62: 141-148.

28. Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y. Comprehensive allelotyping study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. *Hepatology* 2000; 31: 1073-1079.
29. Orsatti G, Theise ND, Thung SN, Paronetto F. DNA image cytometric analysis of macroregenerative nodules (adenomatous hyperplasia) of the liver: evidence in support of their preneoplastic nature. *Hepatology* 1993; 17: 621-627.
30. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. *Semin Liver Dis* 1999; 19: 235-242.
31. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. *Cancer* 2003; 98: 119-127.
32. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. *World J Gastroenterol* 2002; 8: 385-392.
33. Renard CA, Fourel G, Bralet MP, Degott C, De La Coste A, Perret C, Tiollais P, Buendia MA. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. *Oncogene* 2000; 19: 2678-2686.
34. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. *Br J Cancer* 1999; 79: 604-610.
35. Salvucci M, Lemoine A, Azoulay D, Sebah M, Bismuth H, Reynes M, May E, Debuire B. Frequent microsatellite instability in post hepatitis B viral cirrhosis. *Oncogene* 1996; 13: 2681-2685.
36. Salvucci M, Lemoine A, Saffroy R, Azoulay D, Lepere B, Gaillard S, Bismuth H, Reynes M, Debuire B. Microsatellite instability in European hepatocellular carcinoma. *Oncogene* 1999; 18: 181-187.
37. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. *Nat Genet* 2000; 24: 245-250.
38. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. *Biol Chem* 2006; 387: 349-360.
39. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, Ishida M, Hori K, Suou T, Kawasaki H. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. *J Hepatol* 1997; 27: 661-668.
40. Suriawinata A, Xu R. An Update on the molecular genetics of hepatocellular carcinoma. *Semin Liver Dis* 2004; 24: 77-88.
41. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, Kosuge T, Motoo Y, Yamazaki S, Hasegawa H. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. *Lancet* 1990; 336: 1150-1153.
42. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. *Oncogene* 2002; 21: 4863-4871.
43. Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, Degott C, Dejean A. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. *Oncogene* 1999; 18: 6583-6588.
44. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. *Nature Genet* 2002; 31: 339-346.
45. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. *Toxicology* 2002; 181-182: 43-47.
46. Wong CM, Fan ST, Ng IO. Beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. *Cancer* 2001; 92: 136-145.
47. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. *Oncogene* 1999; 18: 4879-4883.
48. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. *Nat Med* 2003; 9: 416-423.
49. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. *J Cancer Res Clin Oncol* 2000; 126: 641-646.

Contributor(s)

Written 09-2006 Raphael Saffroy, Antoinette Lemoine,

Citation

This paper should be referenced as such :

Saffroy R, Lemoine A, Debuire B . . Atlas Genet Cytogenet Oncol Haematol. September 2006 .
URL : <http://AtlasGeneticsOncology.org/Deep/HepatocarcinogenesisID20055.html>

© *Atlas of Genetics and Cytogenetics in Oncology and Haematology*
